CMND

Clearmind Medicine (CMND)

Clearmind Medicine Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CMND

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/20	20 : 57	GlobeNewswire Inc.	Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/06/14	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/06/14	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/06/11	20 : 44	GlobeNewswire Inc.	Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink	NASDAQ:CMND	Clearmind Medicine Inc
2024/05/11	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/05/10	21 : 24	GlobeNewswire Inc.	Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	NASDAQ:CMND	Clearmind Medicine Inc
2024/05/08	05 : 01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CMND	Clearmind Medicine Inc
2024/05/07	20 : 46	GlobeNewswire Inc.	Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2024/05/01	05 : 15	GlobeNewswire Inc.	Clearmind Applies to Cease Being a Reporting Issuer in Canada	NASDAQ:CMND	Clearmind Medicine Inc
2024/04/17	20 : 49	GlobeNewswire Inc.	Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	NASDAQ:CMND	Clearmind Medicine Inc
2024/04/10	20 : 17	GlobeNewswire Inc.	Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	NASDAQ:CMND	Clearmind Medicine Inc
2024/04/09	21 : 07	GlobeNewswire Inc.	Clearmind Medicine CEO Issues Letter to Shareholders	NASDAQ:CMND	Clearmind Medicine Inc
2024/03/19	20 : 55	GlobeNewswire Inc.	Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	NASDAQ:CMND	Clearmind Medicine Inc
2024/03/13	21 : 14	GlobeNewswire Inc.	Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial	NASDAQ:CMND	Clearmind Medicine Inc
2024/03/13	20 : 30	GlobeNewswire Inc.	Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/27	21 : 58	GlobeNewswire Inc.	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/27	21 : 58	GlobeNewswire Inc.	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/23	21 : 06	GlobeNewswire Inc.	Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/20	21 : 14	GlobeNewswire Inc.	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/20	21 : 14	GlobeNewswire Inc.	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/05	21 : 51	GlobeNewswire Inc.	Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China	NASDAQ:CMND	Clearmind Medicine Inc
2024/02/01	22 : 15	GlobeNewswire Inc.	Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center	NASDAQ:CMND	Clearmind Medicine Inc
2024/01/17	01 : 19	GlobeNewswire Inc.	Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement	NASDAQ:CMND	Clearmind Medicine Inc
2024/01/11	23 : 28	GlobeNewswire Inc.	Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement	NASDAQ:CMND	Clearmind Medicine Inc
2024/01/10	21 : 18	GlobeNewswire Inc.	Clearmind Medicine Completed Type A Meeting with the FDA	NASDAQ:CMND	Clearmind Medicine Inc
2024/01/04	21 : 18	GlobeNewswire Inc.	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments	NASDAQ:CMND	Clearmind Medicine Inc
2024/01/04	21 : 18	GlobeNewswire Inc.	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments	NASDAQ:CMND	Clearmind Medicine Inc
2023/12/14	22 : 26	GlobeNewswire Inc.	Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards	NASDAQ:CMND	Clearmind Medicine Inc
2023/12/05	22 : 47	GlobeNewswire Inc.	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment	NASDAQ:CMND	Clearmind Medicine Inc
2023/12/01	22 : 14	GlobeNewswire Inc.	Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial	NASDAQ:CMND	Clearmind Medicine Inc